Galmed Pharmaceuticals Ltd. GLMD 深 滬
等待開盤 04-10 09:30:00 美东时间
0.7852
+0.163
+26.14%
華盛通- 最 高1.26
- 今 開1.16
- 成交量 1.78亿股
- 最 低 0.758
- 昨 收 0.6225
- 總市值 516.77万
- 52周最高 2.68
- 市盈率 靜 --
- 換手率 2701.52%
- 52周最低 0.4111
- 委 比 66.67%
- 總股本 658.14万
- 歷史最高 4870.80
- 量 比 5522.60
- 振 幅 80.64%
- 歷史最低 0.4111
- 每 手 1
- 風險率 0.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Galmed Stock Soars On Brain-Penetrating Aramchol Formulation
Galmed Pharmaceuticals Ltd. shares are trading higher after it announced the development of a brain penetrating new formulation of Aramchol.
04-09 23:04
Galmed Pharmaceuticals shares are trading higher after the company announced the development of a brain penetrating new formulation of Aramchol.
Galmed Pharmaceuticals shares are trading higher after the company announced th...
04-09 20:39
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Galmed Pharmaceuticals (NASDAQ:GLMD) stock increased by 83.2% to $1.14...
04-09 20:05
Galmed Pharmaceuticals Receives Nasdaq Noncompliance Notice, Gets Time Through July 28 To Regain Compliance
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced that the Company
01-31 05:15
Galmed Pharma Granted Patent In South Korea For Aramchol And Rezdiffra Combination Therapy In NASH/MASH And Liver Fibrosis
The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (USPTO), Europe, Canada and other jurisdictions and will expire in the U.S. in July
2025-12-04 21:36
Galmed Pharmaceuticals Granted New Patent for Combination of Aramchol and Rezdiffra (Resmetirom) for MASH Treatment
Galmed Pharmaceuticals Ltd. has announced the grant of new use patents for the combination of its drug candidate Aramchol with Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for the treatment of MAS...
2025-12-04 21:30
Galmed Issues CEO Letter to Shareholders
TEL AVIV, Israel, Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometa...
2025-12-01 21:30
Galmed Pharmaceuticals Q3 EPS $(0.33) Beats $(0.54) Estimate
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.54) by 38.89 percent. This is a 85.71 percent increase over losses of $(2.31) per share
2025-11-26 21:34
Galmed Pharmaceuticals Reports Top-Line Results From AM-001 Phase 1 Bioavailability Study, Demonstrating Enhanced Pharmacokinetic Profile Of Aramchol Meglumine Granules
The top-line results showed that bioavailability of Aramchol meglumine 400mg and 200mg granules is considerably greater, higher by 5-fold and 3-fold respectively, that of the Aramchol free acid 300mg tabletsThe new
2025-11-18 21:44
Galmed Pharmaceuticals Q2 EPS $(0.63) Beats $(0.83) Estimate
Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.83) by 24.1 percent. This is a 61.82 percent increase over losses of $(1.65) per share
2025-08-28 21:36
